GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Short Interest

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Short Interest


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Short Interest

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chongqing Genrix Biopharmaceutical Co's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Short Interest distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Short Interest falls into.


Chongqing Genrix Biopharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Short Interest
Comparable Companies
SZSE:300049 SZSE:002030 SZSE:000990 SHSE:688105 SHSE:600645 SHSE:688382 SHSE:688177 SHSE:605116 SHSE:600866 SZSE:301207 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Website
http://www.genrixbio.com
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines